EZH2 and B-cell non-Hodgkin lymphoma: Despite that recent cancer sequencing projects have reported recurrent point mutations in EZH2 in other hematopoietic tumors e.g., gain of function mutations in B-cell lymphomas [94–97] and loss of function mutations in T-cell acute lymphocytic leukemia [98], myelodysplastic syndromes, and myeloproliferative neoplasms [99–101], no mutations in EZH2 have been identified in hundreds of MM patients whose tumors have been sequenced [42,102].